Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
Maria Pia Amato(University of Florence), María Trojano(University of Bari Aldo Moro), Angelo Ghezzi, Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Franco Granella(University of Parma), Elio Prestipino(University of Florence), Umberto Aguglia(Martin University), Lorenzo Razzolini(University of Florence), Laura Tudisco(University of Florence), Emilio Portaccio(University of Florence), Pietro Iaffaldano(University of Bari Aldo Moro), Francesco Logullo(Marche Polytechnic University), Roberto Fratangelo(University of Florence), Marco Salvetti(Istituto Neurologico Mediterraneo), Giovanna De Luca(University of Udine), Rocco Totaro(San Salvatore Hospital), Angelo Bellinvia(University of Florence), Luisa Pastò(University of Florence), Matilde Inglese(New York University), Mattia Fonderico(Azienda Usl Toscana Centro), Marta Simone(University of Bari Aldo Moro), Simonetta Galgani(IRCCS San Camillo Hospital), Francesco Patti(University of Catania), Giuseppe Salemi, Enrico Millefiorini(Policlinico Umberto I), Patrizia Sola(Azienda Ospedaliero-Universitaria di Modena), Carlo Pozzilli(Sapienza University of Rome), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Eleonora Cocco(University of Cagliari), Giuseppe Lucisano(Center for Outcomes Research and Clinical Epidemiology), Giancarlo Di Battista(Associazione Italiana Sclerosi Multipla), Vincenzo Brescia Morra(Federico II University Hospital), Marika Vianello(Ca' Foncello Hospital), Ciro Florio(Fatebenefratelli Hospital), Maurizia Gatto(Ospedale Generale Regionale Francesco Miulli), Giancarlo Comi(University of Milan), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 90
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624